Literature DB >> 6095084

Tissue-specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses.

D Celander, W A Haseltine.   

Abstract

Inoculation of susceptible strains of mice with the SL3-3 strain of murine leukaemia viruses induces T-cell lymphomas, whereas injection of the Akv strain does not. Recombinant viruses that contain the long terminal repeat (LTR) of the SL3-3 virus and the gag, pol and env genes of the Akv virus are also leukaemogenic. The cell-type specificity of leukaemias induced by viruses containing different LTR sequences is due in part to the ability of the virus to replicate in the appropriate cellular environment. One explanation of the role of the LTR in determination of both cell tropism and leukaemogenic potential is that the LTR encodes tissue-permissive transcriptional elements. We report here that there are differences in the transcriptional activity of the SL3-3 and Akv LTR sequences in different murine cell types, and that the sequences present in the LTR of SL3-3 exhibit significantly enhanced transcriptional activity in T cells compared with the corresponding region of the Akv LTR. The results suggest that transcriptional elements are primary determinants of cell tropism and of leukaemogenicity of these viruses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095084     DOI: 10.1038/312159a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  109 in total

1.  Differential DNA binding of nuclear proteins to a long terminal repeat region of the MCF13 and Akv murine leukemia viruses.

Authors:  F K Yoshimura; J Tupper; K Diem
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression.

Authors:  R A Graves; P Tontonoz; B M Spiegelman
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

3.  Loss of pathogenicity of spleen focus-forming virus after pseudotyping with Akv.

Authors:  K S Jones; S Ruscetti; F Lilly
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

4.  Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers.

Authors:  B Corneliussen; A Thornell; B Hallberg; T Grundström
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.

Authors:  B Hallberg; J Schmidt; A Luz; F S Pedersen; T Grundström
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 7.  The murine leukemia virus LTR in oncogenesis: effect of point mutations and chromosomal integration sites.

Authors:  F S Pedersen; K Paludan; H Y Dai; M Duch; P Jørgensen; N O Kjeldgaard; B Hallberg; T Grundström; J Schmidt; A Luz
Journal:  Radiat Environ Biophys       Date:  1991       Impact factor: 1.925

8.  Different relative expression from two murine leukemia virus long terminal repeats in unintegrated transfected DNA and in integrated retroviral vector proviruses.

Authors:  K Paludan; H Y Dai; M Duch; P Jørgensen; N O Kjeldgaard; F S Pedersen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1.

Authors:  E Verdin; N Becker; F Bex; L Droogmans; A Burny
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

10.  B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.

Authors:  J Lovmand; A B Sorensen; J Schmidt; M Ostergaard; A Luz; F S Pedersen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.